Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis

REFERENCES

1. 1.↵
   1. Jennette JC,
   2. Falk RJ,
   3. Bacon PA,
   4. Basu N,
   5. Cid MC,
   6. Ferrario F,
   7. et al.

   2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Comarmond C,
   2. Pagnoux C,
   3. Khellaf M,
   4. Cordier JF,
   5. Hamidou M,
   6. Viallard JF,
   7. et al;
   8. French Vasculitis Study Group

   . Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65:270–81.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Moosig F,
   2. Bremer JP,
   3. Hellmich B,
   4. Holle JU,
   5. Holl-Ulrich K,
   6. Laudien M,
   7. et al.

   A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013;72:1011–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Novikov P,
   2. Moiseev S,
   3. Smitienko I,
   4. Zagvozdkina E

   . Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine 2016;83:81–4.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Grayson PC,
   2. Monach PA,
   3. Pagnoux C,
   4. Cuthbertson D,
   5. Carette S,
   6. Hoffman GS,
   7. et al;
   8. Vasculitis Clinical Research Consortium

   . Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology 2015;54:1351–9.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Polzer K,
   2. Karonitsch T,
   3. Neumann T,
   4. Eger G,
   5. Haberler C,
   6. Soleiman A,
   7. et al.

   Eotaxin-3 is involved in Churg-Strauss syndrome—a serum marker closely correlating with disease activity. Rheumatology 2008;47:804–8.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Dejaco C,
   2. Oppl B,
   3. Monach P,
   4. Cuthbertson D,
   5. Carette S,
   6. Hoffman G,
   7. et al.

   Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One 2015;10:e0121737.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Stone JH,
   2. Hoffman GS,
   3. Merkel PA,
   4. Min YI,
   5. Uhlfelder ML,
   6. Hellmann DB,
   7. et al;
   8. International Network for the Study of the Systemic Vasculitides (INSSYS)

   . A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912–20.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Zwerina J,
   2. Bach C,
   3. Martorana D,
   4. Jatzwauk M,
   5. Hegasy G,
   6. Moosig F,
   7. et al.

   Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology 2011;50:1823–7.

   OpenUrlAbstract/FREE Full Text